Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 repeated administration study of KTZ-S 2% in healthy Japanese adult males
jRCT2031230012Phase 1Completed
- Sponsor
- SEREN Pharmaceuticals
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketoconazole in seborrheic dermatitis (SD), sponsored by SEREN Pharmaceuticals. Primary endpoints: Blood drug level pharmacokinetics, Local safety at targeted parts and 1 more. Started Apr 2023; status: completed.
02
Drugs
ketoconazole
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on jRCT2031230012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230012.